How to Develop Pharmaceutical Semantic Search for Regulatory and Scientific Documents

Pharmaceutical firms require specially developed pharmaceutical semantic search solutions due to the massive size and diversity of information regulated documents present. Traditional folder and keyword search systems struggle with this information overload and the complexity of its lifecycle. 

Regulatory Affairs, Medical Affairs, Quality, Pharmacovigilance, and R&D teams work with SOPs, submission dossiers, clinical study reports, peer-reviewed publications, product labels, correspondence with health authorities, safety reports, and approved medical responses. Finding a document is but one of the steps. Users also have to determine if it is valid, approved, applicable to the correct product and region, and authorized for their use.

Regulators themselves are moving in this direction. In March 2026, the European Medicines Agency expanded Scientific Explorer, its AI-enabled knowledge-mining tool, to support searches across initial marketing authorisation information and public assessment reports. EMA describes the system as a way to retrieve regulatory precedents more efficiently and improve the consistency and quality of assessments.

Pharmaceutical companies follow suit. McKinsey’s 2025 regulatory affairs benchmark found that roughly 80% of top pharmaceutical companies were modernizing their regulatory information management systems. Leading organizations are implementing structured content, automation, and data-centric regulatory workflows.

AI increases the demand even more. According to Deloitte’s 2026 life sciences research, 48% of surveyed executives expect their companies to be significantly affected by accelerated digital transformation. 41% and 30%, respectively, predicted that generative AI and agentic AI would have a significant impact. Only 22% of respondents admitted to successfully implementing AI at scale, while 9% of companies reported significant ROI. 

The gap is important. Enterprise AI cannot reliably answer scientific or regulatory questions when approved knowledge is scattered across multiple repositories with differences in metadata, permissions, and document versions.

What pharmaceutical semantic search should improve

Semantic search for pharmaceutical documents is becoming part of a wider knowledge and regulatory operating model. It connects enterprise repositories, regulatory information, document lifecycle controls, search, AI, authoring, review, and auditability.

This article explains how to design the data foundation, retrieval architecture, integrations, security controls, AI functions, and validation process required to make that model work.

For readers working with safety operations as well as regulatory content, this guide to developing an automated ICSR processing system explains how structured data, integrations, validation, and workflow automation come together in pharmacovigilance environments. 

Computools case: adding pharmaceutical semantic search to existing content systems 

A useful example comes from Computools’ Retrionex project. Our team worked with a mid-size US pharmaceutical company whose Medical Affairs, Regulatory Affairs, and Scientific Operations teams worked with large volumes of compliance-sensitive information.

The challenge

The company’s knowledge was spread across SOP libraries, publications, approved medical responses, regulatory materials, training portals, and regional repositories. The same topic could appear in several files with different approval states, versions, geographic limitations, and access rights. Employees therefore spent time searching several systems, comparing documents, confirming which version was valid, and checking whether information could be reused in a particular market.

Computools solution

Computools developed Retrionex to solve the client’s pharmaceutical knowledge management issue. Our team implemented it as an intelligence layer above the company’s existing systems of record. A shared ingestion and synchronization layer extracted documents and metadata, normalized them into a common schema, tracked version and approval changes, and updated the search index when source content changed.

Tech stack

Python handled ingestion, preprocessing, metadata enrichment, embedding generation, and retrieval orchestration. 

• Azure AI Search provided vector, semantic, and hybrid retrieval. 
• Azure OpenAI generated answers only from retrieved approved enterprise content. 
• A .NET backend managed repository connections, permissions, queries, references, and audit workflows.
• PostgreSQL stored document metadata, approval information, regional applicability, source relationships, and query history. 
• Microsoft Entra ID supported authentication and role-based access.

The retrieval and generation layers were deliberately separated. Permission rules were applied before retrieval and generation, while the platform blocked unsupported answers if it could not find sufficient approved evidence. Every generated response retained direct references to its supporting documents.

Results

The business results show what this architecture changes operationally:

• average time to find validated information fell from 18 minutes to 10–11 minutes;
• scientific and medical response preparation decreased from 2.5 days to 1.6–1.8 days;
• consistency in approved-content reuse improved by up to 25%. 

The platform also maintained 100% traceability to approved source documents and recorded no unauthorized generation under its grounding rules.

These results point to an important development principle. Pharmaceutical search must control which information enters the index, which version is active, who may retrieve it, and whether AI has enough validated evidence to produce a response.

How to develop pharmaceutical semantic search in 8 steps

Developing pharmaceutical semantic search starts with regulated workflows and information architecture. The following steps address the decisions that determine whether the system reduces real operational work and remains reliable as document volumes, markets, users, and AI functions expand.

Step 1. Define which pharmaceutical decisions the search should accelerate

Before designing the software architecture, identify where employees currently lose time finding, comparing, or validating information.

Relevant workflows include regulatory precedent research, preparation of health-authority responses, medical information requests, submission content reuse, SOP lookup, label comparison, safety investigations, scientific literature research, and market-specific regulatory analysis.

For each workflow, map: user → question → permitted sources → required evidence → output → review requirement → KPI.

A Regulatory Affairs employee searching for previous authority questions has different requirements from a Medical Affairs employee preparing a scientific response. The first may prioritize jurisdiction, procedure, authority, product, and submission stage. The second may need approved response content, scientific references, market restrictions, and medical review status.

The business metrics should reflect these differences. Useful measures for pharmaceutical document search include median time to validated evidence, percentage of successful searches, response-preparation time, approved-content reuse, repeated research avoided, and the number of queries that force employees to switch to another repository manually.

Retrionex followed this logic. The project did not measure success only through technical relevance scores. Search time and response-preparation time became operating KPIs, making it possible to quantify the reduction in manual research.

Without this step, teams risk optimizing search relevance around queries that do little to reduce regulatory or scientific workload.

Step 2. Build a governed pharmaceutical document and metadata model

A search index built from extracted PDF text will not provide enough context for regulated work. The system needs a canonical model that describes both the document and its lifecycle.

Typical metadata should include:

• unique document ID;
• source repository;
• document type;
• product and active substance;
• indication;
• study or protocol;
• regulatory authority;
• jurisdiction;
• submission or application;
• eCTD module or section;
• version;
• approval state;
• effective date;
• superseded status;
• language;
• region;
• confidentiality level;
• access groups.

Where relevant, the model should align product and substance identifiers with established pharmaceutical terminology and standards. EMA’s SPOR program, for example, organizes regulatory master data around substance, product, organisation, and referential information as part of the implementation of ISO IDMP standards.

Document relationships matter as much as individual fields. Instead of treating every extracted chunk as an independent vector, preserve hierarchy: product → submission → document → section → passage.

The same applies to version relationships: original → revision → approved version → superseded version.

This structure allows the pharmaceutical knowledge base to retain provenance when information is split into smaller units for retrieval.

In Retrionex, Computools implemented a custom knowledge schema that standardized document types, versions, approval statuses, regions, product areas, and access attributes across repositories. That common layer gave the retrieval system consistent context even though the underlying sources used different structures.

Poor metadata creates problems that embeddings cannot solve. A model may identify a semantically relevant paragraph while failing to recognize that the document was withdrawn, replaced, restricted to another market, or never approved.

For a broader view of the data architecture behind healthcare AI and analytics, see how to build a healthcare data platform. It covers how organizations can consolidate fragmented healthcare information into a structured foundation for operational and AI use. 

Step 3. Combine keyword, semantic, and metadata-based retrieval

Vector similarity is useful for finding conceptually related passages, but pure vector search is a weak fit for many pharmaceutical queries.

Users frequently search for exact product names, study identifiers, protocol numbers, submission sequence numbers, regulatory terminology, chemical entities, adverse event terms, and specific wording used by authorities. Exact matching remains important in these cases.

A modern regulatory document search pipeline should therefore combine several mechanisms: query processing → identity and metadata filtering → lexical/BM25 retrieval + vector retrieval → semantic reranking → document reconstruction → ranked evidence.

Lexical retrieval captures exact expressions and identifiers. Vector retrieval finds relevant material even when the query and document use different wording. Metadata filtering restricts results by factors such as product, market, approval status, and document type. Reranking evaluates the candidate set using richer semantic context.

Recent research supports this approach. A 2026 study of automated regulatory intelligence analyzed a source corpus of more than 442,000 regulatory documents and used combined semantic-similarity and keyword scoring. The system reached 95% recall for high-confidence relevant content, showing why hybrid methods are valuable when missing a relevant regulatory document carries real operational cost.

NLP for pharmaceutical documents can improve the pipeline further through entity extraction, abbreviation expansion, synonym mapping, substance and product recognition, study-ID detection, jurisdiction classification, and query-intent analysis.

For example, a user may search for “changes to storage conditions for Product X in the EU.” The system should recognize Product X, identify the EU jurisdiction, distinguish storage conditions as the topic, filter superseded material, and then retrieve semantically relevant passages even if the exact phrase “storage conditions” does not appear.

This combination makes pharmaceutical data retrieval and semantic search for regulatory documents more precise without sacrificing exact-document lookup.

Step 4. Add grounded generative AI capabilities

Semantic retrieval and generative AI should remain separate architectural layers.

Users should still be able to search, inspect, filter, and open documents when answer generation is disabled. This is particularly important when an organization introduces AI search for pharmaceutical documents gradually or limits generative functions to specific teams.

For RAG-based workflows, use a controlled sequence: question → authorized retrieval → reranking → evidence threshold → generation → source attribution → user review.

The model should receive only the documents permitted for that user and query. Generated statements should link back to the source passages that support them. The interface should expose document version, approval status, jurisdiction, and source repository where these attributes affect interpretation.

A critical feature is abstention. If the retrieval layer cannot find enough approved evidence, the system should return an “insufficient evidence” state rather than fill the gap from general model knowledge.

Retrionex used this model. Computools restricted generation to retrieved approved content and blocked unsupported answers when the available evidence did not satisfy the grounding rules.

This design also matches the direction of current regulatory guidance. In January 2026, FDA and EMA jointly published ten principles for good AI practice in drug development. They emphasize a defined context of use, risk-based implementation, data governance, documentation, performance assessment, and lifecycle management.

For a search platform, those principles translate into clear limits on what AI is allowed to answer, documented retrieval and generation logic, measurable acceptance criteria, controlled model changes, and persistent source traceability.

Another useful perspective is how to build an AI system for clinical documentation, which examines how AI can work with sensitive clinical information while maintaining structured workflows, source control, and review requirements. 

Step 5. Connect search With RIM, DMS, submission, and scientific systems

Semantic search should normally sit above existing systems of record.

Depending on the organization, integrations may include:

• regulatory information management systems;
• enterprise document management;
• eCTD and submission publishing platforms;
• quality and SOP repositories;
• clinical document repositories;
• scientific publication databases;
• SharePoint and Microsoft 365;
• medical information systems;
• pharmacovigilance systems where the use case requires them.

This distinction is important when connecting a pharmaceutical document management system with regulatory information management. The DMS may remain responsible for controlled documents and approval workflows, while RIM stores regulatory entities, commitments, registrations, and submission data. Semantic search creates a unified discovery layer across those systems without changing which system owns the record.

The ingestion pipeline should respond to lifecycle events: new or updated source → extraction → metadata validation → classification → embedding generation → index update → superseded-content handling → audit record.

An approved document changing to superseded status should change search behavior automatically. A draft should not become available simply because the file exists in a connected repository.

Retrionex used a shared ingestion and synchronization layer to solve this problem across sources with different formats, metadata structures, versioning models, and update cycles. The search index changed as the source documents changed, without forcing the client to migrate its repositories.

The move toward eCTD v4.0 makes lifecycle-aware architecture increasingly relevant. FDA currently accepts new NDA, BLA, ANDA, IND, and master file applications in eCTD v4.0 and continues updating its v4.0 standards and technical guidance. In Europe, optional use has begun for new centrally authorised product marketing authorisation applications, with further implementation phases continuing through 2026 and 2027.

A search platform therefore benefits from understanding submission structures and lifecycle relationships rather than indexing regulatory content as a flat collection of PDFs.

Launch pharmaceutical semantic search within 1–3 months, and help regulatory and scientific teams cut document retrieval time, reduce review effort, and accelerate submission timelines by giving them instant access to the right evidence across complex document repositories.

Contact Us →

Step 6. Apply security and permissions before retrieval

Permission enforcement must happen before content reaches the model.

A basic controlled flow is: enterprise identity → user attributes → permitted corpus → retrieval → generation.

Depending on the operating model, the architecture may use SSO, RBAC, attribute-based rules, product and region restrictions, document-level ACLs, encryption, private endpoints, audit logging, retention controls, secrets management, and data-residency policies.

Query-level authorization may also be necessary. A user may have access to a repository but still lack permission to retrieve particular product, market, or confidential development information.

Retrionex used Microsoft Entra ID for authentication and role-based access, then applied document and query permissions before retrieval and generation. The system also stored query history and audit records so answers remained traceable to their evidence and access context.

Security directly affects business adoption. Regulatory and medical teams cannot rely on a system that risks exposing restricted documents, presenting stale content, or producing answers with unverifiable provenance.

Compliance requirements should be assessed against the system’s intended use. Where the platform participates in GxP processes or maintains regulated electronic records, organizations may need controls addressing validation, data integrity, audit trails, change management, electronic records, and applicable requirements such as 21 CFR Part 11 or EU Annex 11. The exact scope should follow the workflow and regulatory context rather than assuming every semantic search deployment has identical validation obligations.

Healthcare AI also places additional demands on infrastructure and access control. Cloud security in healthcare businesses provides a closer look at protecting sensitive data, managing cloud risks, and maintaining security across connected healthcare systems. 

Step 7. Extend search into regulatory intelligence and knowledge automation

Once the retrieval foundation is reliable, the same infrastructure can support more advanced functions.

These features move AI-powered regulatory document search closer to operational workflow automation. A Regulatory Affairs specialist could receive a notification when new guidance affects an assigned market, open a comparison with the previous version, identify affected internal content, and review related submissions without manually checking multiple systems.

EMA’s Scientific Explorer provides a current example of this direction. Its March 2026 expansion allows authorized regulators to search initial marketing authorisation information and assessment reports to retrieve relevant precedents more efficiently.

The limiting factor remains data quality. AI functions depend on reliable metadata, version control, permissions, source lineage, and structured relationships. Adding more advanced models before fixing these dependencies simply moves existing information problems into an AI interface.

Step 8. Validate retrieval quality and optimize it after launch

A pharmaceutical search platform needs a defined evaluation framework before broader deployment.

Start by creating a benchmark set from real queries. Regulatory, Medical Affairs, Quality, and scientific subject-matter experts should identify the documents and passages expected for each question.

Evaluate retrieval with metrics such as:

• Recall@K;
• Precision@K;
• Mean Reciprocal Rank;
• nDCG;
• successful-query rate;
• irrelevant-result rate;
• source citation accuracy;
• grounded-answer rate;
• correct abstention rate;
• stale-document retrieval;
• permission violations;
• index synchronization failures;
• latency.

Do not rely on one aggregate score. Exact identifier searches and conceptual scientific questions behave differently.

Create separate tests for: exact lookup | scientific question | regulatory precedent | product-specific query | cross-market comparison | SOP search.

The content pipeline also requires realistic testing. Regulatory repositories contain long PDFs, tables, scanned material, XML, appendices, duplicate files, multiple languages, inconsistent abbreviations, and conflicting versions. Chunking and parsing logic should preserve section context rather than splitting information at arbitrary token boundaries.

Post-launch monitoring should examine failed queries, low-confidence sessions, searches followed by manual repository switching, frequently filtered results, stale content incidents, and user-selected documents. These patterns reveal where metadata, synonyms, ranking, or corpus coverage need adjustment.

Model changes also require control. When teams replace an embedding model, reranker, LLM, or chunking strategy, rerun the benchmark set before production release and compare results against the existing baseline.

Deloitte’s midyear 2026 life sciences research illustrates the broader problem: 71% of respondents reported at least some progress in AI deployment, but only 45% reported measurable improvement and 13% reported measurable improvements at scale. A search initiative therefore needs operational and retrieval KPIs from the beginning, not after AI usage grows.

For a closer look at how AI can support safety workflows beyond document retrieval, see how to build an AI pharmacovigilance automation platform for ICSR processing. It explores AI-assisted case processing, automation, validation, and the data controls required around pharmacovigilance operations. 

Why choose Computools for pharmaceutical semantic search development

Pharmaceutical search brings together enterprise data, regulated content, AI, security, and workflow design. Computools maps how information moves across the organization, which systems remain authoritative, who can access specific content, and what evidence employees need before acting on search results. This keeps the platform aligned with regulatory workflows and operational goals.

1. Reduce search and verification time

Through its healthcare software development services and pharmaceutical software development, Computools works with regulated environments where document status, traceability, security, and integrations affect daily performance.

Clients gain faster access to relevant evidence, fewer manual verification steps, and more consistent reuse of approved content across Regulatory Affairs, Medical Affairs, Quality, and R&D.

2. Turn fragmented repositories into a reliable knowledge layer

Computools’ data engineering services establish the foundation for reliable retrieval through ingestion pipelines, normalization, metadata models, source synchronization, and structured data processing.

This allows fragmented repositories to operate as a connected knowledge layer, making duplicate, outdated, or poorly classified content easier to manage and search results easier to validate.

3. Introduce AI with controlled sources and permissions

AI development adds semantic retrieval, NLP, RAG, AI orchestration, and model evaluation.

Teams can find and compare relevant information faster, automate repetitive research, and introduce AI-assisted workflows while preserving document lineage, access rules, and source grounding.

4. Give teams one interface for search and validation

Computools’ web development services connect retrieval technology with practical search, review, source-validation, and administration workflows.

Employees can search, filter, compare, and validate information without repeatedly switching between systems, reducing research time and unnecessary manual work.

5. Connect pharmaceutical knowledge with wider healthcare systems

Computools’ experience with hospital software development services supports scenarios where pharmaceutical information must interact with clinical, provider-side, or other healthcare platforms.

This allows clients to extend knowledge workflows across departments and systems without creating additional data silos.

6. Scale search without replacing existing systems

Retrionex demonstrates this approach in practice. The client’s repositories remained in place while Computools connected them through normalized metadata, hybrid semantic retrieval, source-grounded AI, permission enforcement, and full traceability.

The result was faster document search, more consistent approved-content reuse, and a scalable architecture without disrupting systems already embedded in daily operations.

Final thoughts

Pharmaceutical and regulatory knowledge is becoming too distributed, interconnected, and frequently updated for employees to depend on folders and exact keyword matching. The business cost appears in repeated searches, slower authority responses, duplicated content, inconsistent use of approved material, and additional verification work.

Effective pharmaceutical semantic search addresses these problems. Its implementation requires a controlled document model, lifecycle-aware synchronization, hybrid retrieval, permissions, source lineage, measurable relevance, and defined AI boundaries.

The system’s value should be visible in faster access to validated evidence, shorter response cycles, better reuse of approved content, fewer document errors, and a safer foundation for future pharmaceutical AI workflows.